Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating restated by equities researchers at Numis Securities Ltd in a research report issued to clients and investors on Monday. They currently have a GBX 267 ($3.30) target price on the stock. Numis Securities Ltd’s price target points to a potential upside of 120.66% from the stock’s previous close.

Several other research firms have also recently weighed in on ERGO. N+1 Singer reiterated a “buy” rating on shares of Ergomed PLC in a report on Monday, September 26th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 271 ($3.35) price objective on shares of Ergomed PLC in a research note on Thursday, September 22nd.

Ergomed PLC (LON:ERGO) opened at 120.75 on Monday. Ergomed PLC has a 12-month low of GBX 117.00 and a 12-month high of GBX 172.00. The firm’s market cap is GBX 37.57 million. The company has a 50-day moving average price of GBX 120.15 and a 200-day moving average price of GBX 131.80.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Ergomed PLC Company Profile

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with's FREE daily email newsletter.